Lapress

Lercanidipine hydrochloride, the active ingredient in Lapress, is a calcium channel blocker presented as an oral tablet for oral use. It is used to lower elevated blood pressure in adults with hypertension. GNH USA supplies Lapress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lapress, a calcium channel blocker, is employed in the management of arterial hypertension. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: lowers elevated systolic pressure, improving cardiovascular risk profile. - Hypertensive patients with cardiovascular risk: provides sustained blood pressure control to lower risk of stroke and myocardial infarction.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate in some patients. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of face, lips, or throat. - Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: start at the lowest effective dose and monitor for dizziness. - Concomitant antihypertensives: assess for additive blood pressure‑lowering effects. - Severe aortic stenosis: contraindicated due to risk of sudden drop in pressure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lercanidipine may interact with several drug classes, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration leading to excessive blood pressure reduction. - Other potent antihypertensives: may cause additive hypotensive effects. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: can enhance electrolyte disturbances. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: combined use may increase risk of bradycardia.